Still holding up. Very good sign!
Love how it held up. Normally these sell off after big days.
No kidding. I bought back in September and have doubled my money.
Announced today - 9b / $87
I think someone just figured out why, a little front loading tipster caught some wind back then, but seems to have been a bit off on what strike price to pick, if they did get a leak, with what ever they make, they can request the SEC and Fed's to incrust diamonds into the handcuffs when they come to take them for a ride downtown.
Not sure just saw it on the news yesterday.
Wow, do you know the offer price?
MSKCC/PPHM poster # 1651 at AACR in April 2017 highlights safety in pre-clinical CAR-T studies. Note conclusions.
$JUNO Hits Support For Technical Bounce Trade Here...
Shares of Juno Therapeutics Inc (NASDAQ:JUNO) have fallen sharply over the last two trading days. On a technical basis, the biotech hit major support when it broke through $46.00. This is a bounce level for investors looking for a quick couple day bounce. Look for a snap back to $50 in the coming days.
Sir char char, how many deaths has JUNO had during these trials? Very toxic stuff ! I hope they don't try and cover up anymore deaths . They sure forgot to mention the last 2 they had until they were called out on it? Good Luck just can't believe they went to $20 and are now at close to $60 with so many deaths caused by there treatment? Crazy!
$56.12 is where I got 2/3 out here!
JUNO at 45.40 here trying to breakout of its recent 41-45 channel. Lets go!
I'm up over a grand in this stock. Should I time it or hold longer?
Yeah I agree. All these bio ticks usually get hit by a wave of class lawsuits shortly after bad news.. which usually causes additional panic on market and father drop in pps. My bid is lower.
Two more patients died, I would wait awhile to let that soak in before buying
JUNO could be a good buy here..
Though it's possible it will dip below $20 when lawsuits start hitting wires again soon
Have a bid in..
CELG looking at alternative approaches and do realize there is no exact science. As TREND1 says about other stocks I own or follow "stock price tells the story." The same could be said for JUNO.
Still like the technology just not sure I like this particular company. Typical biotech huge risk, but huge reward potential. No position, but watching closely for possible entry.
"Our JCAR017 plans remain on track. We expect to be able to have our first approval in the United States as early as 2018," Bishop said."
"Although we have experienced a setback in the ROCKET trial with the clinical hold…we are optimistic that we will achieve results comparable to those in the phase I trial. These results should provide the basis for an accelerated approval," according to Bishop."
No current position, but did have some puts when it tanked from $42 to $28 on PhaseII trial halt and I sold them at that time. I'm actually looking to get back in long, but was thinking we might see previous lows in the $22-$24 range. Probably missed that one, but a believer in the technology.
I only bought puts because I thought it was overvalued and felt the IBB was under pressure 2-3 weeks ago. Now the market if making new highs (though I'm not sold on a break out of the indexes that have transpired in the last week. Sitting and watching for the time being.
*****AML Therapies: Seattle Genetics Vs. GlycoMimetics
ALSO JUNO MENTIONED
Jul. 15, 2016 8:10 AM ET
About: GlycoMimetics (GLYC), SGEN, Includes: JUNO
Follow (1,085 followers)
Long only, tech, biotech, research analyst
•Acute Myeloid Leukemia is very difficult to treat successfully.
•Seattle Genetics SGN-CD33A started a Phase 3 trial.
•GlycoMimetics GMI-1271 started Phase 2 trial.
•There are other competitors, but it is unlikely AML will be 100% cured by any one therapy.
Hypi JUNO is working on a product that does not exist.
That is why 3 people (all under 25) can die, but the FDA still approves
resumption of phase 2 trial.
It will save lives when approved.
Great news. It should bounce to $34 next week imo
Juno buys early-stage biotech for access to immuno-oncology candidate
Jul 14 2016, 16:32 ET | About: Juno Therapeutics (JUNO) | By: Douglas W. House, SA News Editor